This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Lanadelumab parenteral

Updated 2 Feb 2023 | Hereditary angioedema


Injections of lanadelumab.

These products have been produced by recombinant technology using Chinese Hamster Ovary (CHO) cell lines.

Drugs List

  • lanadelumab 300mg/2ml solution for injection pre-filled syringe
  • TAKHZYRO 300mg/2ml solution for injection pre-filled syringe
  • Therapeutic Indications


    Hereditary angioedema



    Initial dose: 300mg every 2 weeks.

    Patients who remain attack free with treatment: consider 300mg every 4 weeks.

    Additional Dosage Information

    Missed Dose
    If a dose is missed, administer as soon as possible, ensuring there are at least 10 days between doses.


    To be administered as a subcutaneous injection into the abdomen, thighs or upper outer arms. It is recommended that the injection site is rotated.


    Children under 12 years

    Precautions and Warnings


    Treatment to be initiated and supervised by a specialist
    Contains polysorbate
    For subcutaneous use only
    Record name and batch number of administered product
    Self-admin. - only if adequately trained and have access to expert advice
    Vary injection site during prolonged therapy
    Advise patient to stop therapy & contact Dr if hypersensitivity signs occur
    May affect results of some laboratory tests

    Pregnancy and Lactation


    Use lanadelumab with caution during pregnancy.

    The manufacturer does not recommend using lanadelumab during pregnancy. Animal studies do not indicate direct/indirect harmful effects relating to reproductive or developmental toxicity. At the time of writing there is limited human data available. Risks are unknown.


    Use lanadelumab with caution during breastfeeding.

    The manufacturer notes that human immunoglobulins are excreted in breast milk during the first few days after birth but this soon decreases to low concentrations. A risk to the breastfed infant during this time cannot be excluded, however after this period lanadelumab can be used if clinically needed.

    Side Effects

    Alanine aminotransferase increased
    Aspartate aminotransferase increased
    Hypersensitivity reactions
    Local reaction at injection site
    Maculopapular rash

    Effects on Laboratory Tests

    Interference with coagulation test
    Lanadelumab can increase activated partial thromboplastin time (aPTT) due to its interaction with the aPTT assay. In patients treated with this medication, no increases in aPTT were associated with abnormal bleeding adverse events.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: May 2021

    Reference Sources

    Summary of Product Characteristics: Takhzyro 300mg solution for injection in vial. Shire Pharmaceuticals Ireland Limited. Revised July 2020.
    Summary of Product Characteristics: Takhzyro 300mg solution for injection in pre-filled syringe. Shire Pharmaceuticals Ireland Limited. Revised July 2020.

    NICE Evidence Services Available at: Last accessed: 20 May 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.